2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Bleeding and Clotting, Thromboembolism, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4442 How adolescents and young adults with sickle cell disease conceptualize trust in clinicians: A qualitative analysis

Adam René Pérez Rosenbaum, MD, Molly Ream, PhD2, Elizabeth Jin, BA3, Gabriela Pearson, BA4, Manan M. Nayak, PhD, MA5, Natasha M. Archer, MD, MPH6, Abby R. Rosenberg, MD, MA, MS7
1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States

Background: Trust in science, healthcare, and clinicians is essential to the patient experience. Trusting relationships between patients and their clinicians correlate with many positive health outcomes, including medication adherence, retention to care, and better recall of important medical conversations. However, despite its importance, trust in healthcare and clinicians has decreased over the 2020s. As adolescents and young adults (AYAs) assume increasing autonomy and responsibility for their own medical decision-making, improving trust in their clinicians and healthcare is particularly salient for this demographic. AYAs with sickle cell disease (SCD) are at a particularly high risk for poor health outcomes, which trust could potentially help ameliorate. Despite its importance globally and in this context, trust in clinicians amongst AYAs with SCD is understudied. We aimed to qualitatively assess what trust means to AYAs with SCD, factors that shape it, and why it matters. 

Methods: We conducted 30–60-minute semi-structured interviews with AYAs (ages 13-25) with SCD who are followed at a major SCD center, who completed a one-time survey about trust in their medical team, and who opted into a follow-up interview. We obtained informed consent from participants over 18 years, and parental consent and patient assent from participants under 18 years. Participants who were unable to provide consent in English, identify a primary hematologist, or who were primary patients of the principal investigator were excluded. Interview topics included understanding the nature of trust, factors that strengthen or erode trust, and in what ways trust impacts patients. Interviews were conducted by a male, Latino physician or a female, white psychologist. Interviews were conducted via Zoom, recorded, and transcribed verbatim. We used rapid qualitative analyses to summarize interview data in structured matrices, which were iteratively reviewed by the analytic team to identify and refine themes.

Results: Between October 2025 and July 2026 46 participants enrolled in the quantitative portion of this study, 29 opted into the qualitative follow-up (63%). 14 completed the follow-up interview (48%). Most were female (64%), had HbSS (79%), and the mean age was 18 years (range 13-22). We identified three major themes: 1) trust evolves as patients age and develop: Patients with SCD described longitudinal relationships with their hematologist. When patients were younger, they tended to trust their parents; therefore, their parents’ relationship with their hematology clinician influenced their own. As patients aged, feeling respected by their clinician helped establish a more personal trust in their clinician. Longitudinal providers play an important role to “guide [patients] to gain more independence when it comes to medical issues”; 2) recognizing one’s personhood outside of SCD earns trust: AYAs described their SCD as only one aspect of who they were. Patients recognized that clinicians taking the time to learn what’s important to them as an entire person was vital to trust, such as educational goals and extracurricular activates. Failure to recognize the complex intersectionality of patients negatively impacted the therapeutic relationship: “He didn’t let me live my life how I want to live it”; 3) trust matters for health outcomes: AYAs described that trust in their medical team was important for a variety of decisions, ranging from deciding to “share when I think something, like, negatively about something, or not as much comfort about something” to taking medications as recommended, to considering curative therapy options.

Conclusions: AYA’s with SCD recognized trust as an important factor that evolved over time as they age, and it influenced their health behaviors and outcomes. Providers who built relationships with AYA’s beyond their diagnosis and provided longitudinal care were more likely to have earned AYA’s trust. Practices of promoting AYA growth and respect for their developing autonomy, preferences, and goals are teachable and actionable skills which may be important for pediatric hematologists to embody as they work to promote lifelong wellness in this high-risk population.

Funding: This project was funded in part by the Dana-Farber Pediatric Hematology/Oncology Outcomes Sciences Research Grant.

Adam René Pérez Rosenbaum, MD: No relevant conflicts of interest to declare.